Abstract Number: 1269 • ACR Convergence 2021
The Burden of Systemic Lupus Erythematosus Patients in the United States – Evidence from the Medical Expenditure Panel Survey (2016-2018)
Background/Purpose: Due to the heterogeneity of systemic lupus erythematosus (SLE), clinical characteristics, quality of life (QOL), social determinant of health (SDOH), health care utilization (HRU),…Abstract Number: 0584 • ACR Convergence 2020
Total Cost of Care for Patients with Rheumatoid Arthritis
Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…Abstract Number: 0585 • ACR Convergence 2020
Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
Background/Purpose: The “Joint Resources – Sedentary Behaviour” randomised controlled trial (RCT) (1,2,3) aimed to reduce sedentary behaviour in patients with rheumatoid arthritis (RA) by means…Abstract Number: 0588 • ACR Convergence 2020
Feast or Famine? An Institutional Assessment of Hydroxychloroquine Screening Practices
Background/Purpose: Hydroxychloroquine (HCQ) is a generally safe and widely used rheumatologic drug. Maculopathy is an adverse effect in < 1% in the first 5 years…Abstract Number: 0609 • ACR Convergence 2020
Impact of Depressive Symptoms, Anti-depression Treatment on Direct Medical Costs Among Medicare Beneficiaries with Knee Osteoarthritis (KOA)
Background/Purpose: Depressive symptoms are prevalent among knee OA (KOA) patients and likely lead to additional medical costs. We sought to quantify the prevalence of depressive…Abstract Number: 1265 • ACR Convergence 2020
2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations
Background/Purpose: The latest 2019 Lupus Classification criteria score (CCS) is based on weighted criteria and has been shown to predict 10-year mortality1. Our previous study…Abstract Number: 1618 • ACR Convergence 2020
Frequency and Cost of Repeat HLA-B27 Testing Within the National Capital Consortium over a Calendar Year
Background/Purpose: Human leukocyte antigens (HLAs) are proteins encoded for by the major histocompatibility complex located on the short arm of chromosome six. One such allele,…Abstract Number: 1960 • ACR Convergence 2020
Cost-effectiveness of Surgical and Non-Surgical Weight Loss Programs for Morbidly Obese Patients with Knee Osteoarthritis
Background/Purpose: Growing numbers of knee osteoarthritis (KOA) patients are morbidly obese (BMI ≥ 35 kg/m2). Evolving evidence suggests weight reduction may delay the structural progression…Abstract Number: 1966 • ACR Convergence 2020
Improving Value Concordant Care Through Increased Use of Subcutaneous Methotrexate in Rheumatoid Arthritis
Background/Purpose: Rheumatoid Arthritis (RA) is an expensive disease which untreated can lead to disability and socioeconomic burden. This high cost of treatment impacts the use…Abstract Number: 0478 • ACR Convergence 2020
Increasing Awareness of Advocacy During Early Career – a Web-Based Educational Program
Background/Purpose: In 2015, the American College of Rheumatology (ACR) began Advocacy 101 in person-education for Fellows in Training (FIT) and physicians to encourage participation in…Abstract Number: 0567 • ACR Convergence 2020
Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care
Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…Abstract Number: 0569 • ACR Convergence 2020
Ability and Willingness to Utilize Telemedicine Among Rheumatology Patients – a Cross Sectional Survey
Background/Purpose: Telemedicine (TM) is the delivery of health care services using information and communication technologies. TM presents unique opportunities and benefits specifically in rheumatology as…Abstract Number: 0572 • ACR Convergence 2020
Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
Background/Purpose: The benefits of tapering are a decreased risk of long-term adverse events and a reduction of health care costs, especially when bDMARDs are tapered.…Abstract Number: 0576 • ACR Convergence 2020
Medical Savings of Timely Rheumatoid Arthritis Diagnoses
Background/Purpose: Previous studies suggest that early rheumatoid arthritis (RA) recognition and treatment provides greater clinical benefits than treatment started later in the disease course. However,…Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…
ACR Meeting Abstracts